Arbitrage SBIR Phase II Bridge via Convertible Note Financing
- Organization
- National Science Foundation (NSF)
- Sector
- Early-stage biotech companies with SBIR Phase I awards
- Location
- United States
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I funding to ENDURE BIOTHERAPEUTICS for a precision microbiome therapeutic platform targeting PKU, creating a structural 6-month funding cliff and commercial execution gap despite government validation of the technology.
Market catalyst
Structural 6-month funding cliff between SBIR Phase I ($305K) and Phase II ($1M+) creates immediate cash flow crisis for ENDURE BIOTHERAPEUTICS despite government validation of their technology platform, forcing them to accept unfavorable bridge terms or risk losing momentum.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.